clinical trial · NCT07751250
Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus Matched Participants With Normal Hepatic Function
Healthy ParticipantsHepatic ImpairmentCasdatifan
brief summary
The purpose of the study is to compare the single dose PK of casdatifan between participants with moderate hepatic impairment (HI) and healthy matched control participants with normal hepatic function.
started
Aug 14, 2026
primary completion
May 1, 2027
completion
May 1, 2027
last updated
Sep 4, 2026
official title
A Phase 1, Open-Label, Single-Dose, Parallel-Group Study to Evaluate the Pharmacokinetics of Casdatifan (AB521) in Participants With Moderate Hepatic Impairment Compared to Healthy Matched Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol